News

Biocurious: With psychedelic therapies gaining cred, Tryptamine offers patients and investors the trip of a lifetime
The CEO of local psychedelic drug developer Tryptamine Therapeutics (ASX:TYP), CEO Jason Carroll isn’t afraid to make the big ...